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assessment issues should be addressed in the accompanying
note through consideration of multiple sources of relevant
information.
In addressing the multidimensional nature of the experience
of pain, Dr Alcock does not object to the addition of the word
“cognitive” to characterize the experience, but demurs on the
use of the term “social,” suggesting it “may not be well suited to
a definition of pain,” concluding that terms referring to
sensation, thoughts, feelings, and behaviours are sufficient.
Nevertheless, he observes that the biopsychosocial framework
for pain argues for bidirectional relationships among “pain,
biomedical, psychological, and social factors.” We note that
increasing attention to the neurobiology of human interac-
tions2,4,7 argues the ubiquity of social factors in human action
and decisionmaking.We have an opportunity that should not be
missed to explicitly acknowledge the importance of social
factors as features of pain.
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Ultramicronized palmitoylethanolamide treatment in
central neuropathic pain following longstanding
spinal cord injury: try to extinguish the fire after
everything was burned
Letter To Editor:
In a recent issue of PAIN, Andresen et al.3 reported the results of
a randomized, double-blind, placebo-controlled clinical trial
examining the effect of ultramicronized palmitoylethanolamide
(PEA-um) as add-on therapy on neuropathic pain following spinal
cord injury (SCI), as well as the effects on spasticity and
psychological functioning. The ineffectiveness of PEA-umcontrasts
with current literature describing the beneficial effects of PEA-um in
neuropathic pain.12,13 As the authors discuss, reasons for this
negative outcome could relate to several factors (patient heteroge-
neity regarding causes and levels of SCI, concomitant medications
and unresponsiveness to pain treatment). Unfortunately, the study
does not provide details on medication dosing or on the length of
pharmacological treatment before administration of PEA-um.Given
a baseline pain score of 6.4, although most patients were already
receiving a large amount of medications for pain and spasticity, it is
difficult to expect a beneficial effect of PEA-um. In the trial by
Andresen et al, in the PEA-um group, 77.7% of patients were
already taking gabapentinoids (in contrast to 54% in the placebo
group) along with many other drugs in combination (weak and
strong opioids, antidepressants, other drugs) so, probably, they
represent a group of patients particularly unresponsive to pain
treatments. Furthermore, the timing of treatment effects on glia
could be crucial in these patients. There is evidence that glial
activation plays amajor role in the development andmaintenance of
neuropathic pain after SCI in an animal model.9 For this reason,
specific treatments aimed to reduce glial activation have been
already tested in the early stages of spinal injury.15 In both treatment
groups in the Andresen et al. trial, the duration of time from the
trauma is relevant (9.4 years in the PEA-um group, 11.1 years in the
placebo group) andmakes a therapeutic response to a glial inhibitor
unlikely when the glial activation may have already produced
permanent structural modifications. Moreover, no explanation is
given as to why there was a significant reduction of acetaminophen
consumption in the PEA-um group compared with the placebo
group. Some experimental data in the animal model of neuropathic
pain have shown synergistic activity of PEA combined with
acetaminophen and such synergistic effects might explain the
observed reduction of acetaminophen consumption in the treat-
ment group.6 In the trial by Andresen et al, the PEA-um group and
the placebo group were not homogeneous with respect to gender.
Specifically, in the placebo group, there were only 5 female patients
compared with 14 in the PEA-um group. Although the possibility
that gender is a predictor of the severity of neuropathic pain is
controversial,4,5 research using an animal model of neuropathic
pain showed a different response in regulating pain hypersensitivity
mediated by microglia depending on gender.10 Andresen et al.
reported that female gender is a risk factor for the development of
neuropathic pain after SCI.2 In our opinion, therefore, it is necessary
that in the clinical pain studies, different groups must be
homogeneouswith respect to gender.Despite the lackof significant
results emerging from the trial of Andresen et al, an ever-growing
body of evidence documenting the pain-relieving, anti-inflammatory
and neuroprotective actions of PEA should encourage further
studies on PEA-um effects in SCI particularly at shorter times
postinsult.1,7,8,11,14
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Reply
Letter To Editor:
We thank Dr. Polati et al. for their interest in our study. Polati
et al. emphasize what we also conclude from our study, namely
that ultramicronized palmitoylethanolamide (PEA-um) has no
effect as add-on therapy in chronic neuropathic pain after spinal
cord injury (SCI), although this does not preclude an effect of
PEA in the early stages of SCI or in patients without concomitant
treatment.
In some aspects, however, we do not entirely agree with
Polati et al. They note, for example, that the negative results of
our study contrast with the current literature. However, most
studies suggesting an effect of PEA-um in neuropathic pain
are preclinical studies, open-label studies, or case reports,
and the poor predictive value of preclinical animal models is
well known in the field of neuropathic pain.4 In fact, only 2
randomized, controlled, double-blind studies of PEA in
neuropathic pain have been published. Both studies, pub-
lished in Spanish by the same group, showed an effect of PEA
in lumbosciatica,1,3 but the effect of PEA or PEA-um in other
neuropathic pain conditions has not been examined in
randomized controlled trials.
Polati et al. also argue that the large number of patients taking
medications for pain and spasticity in our study makes it difficult
to expect a beneficial effect of PEA-um. This may not
necessarily be the case. Two large studies documenting
a pain-relieving effect of pregabalin on SCI-related neuropathic
pain included patients with a mean pain duration of 9 to 10
years, similar to our study, and the studies also showed that of
these patients 91% to 97% received various concomitant drug
treatments while looking at only concomitant pain medications,
the percentage was between 69% and 76%.2,5 Polati et al. also
point out that the PEA-um and placebo groups were not
homogeneous with respect to sex. However, we found no effect
of PEA-um when separating the groups into men (n 5 49) and
women (n 5 19).
In conclusion, we agree that although our study showed no
effect of PEA-um in chronic neuropathic pain after SCI, it does
not provide any data on a possible early preventive effect of
PEA-um.
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